Shehnaz K. Hussain
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Shehnaz K. Hussain has a total of 73 co-authors. Here are the top co-authors by number of shared publications:
Otoniel Martínez-Maza
Department of Epidemiology, Fielding School of Public Health, University of California, Los Angeles (UCLA), Los Angeles, CA
6 shared publicationsRoger Detels
Department of Epidemiology, Fielding School of Public Health, University of California, Los Angeles (UCLA), Los Angeles, CA
5 shared publications- Zuo-Feng Zhang
Department of Epidemiology, Fielding School of Public Health, University of California, Los Angeles, Los Angeles, USA
4 shared publications Jan Sundquist
Center for Primary Health Care Research, Lund University/Region Skåne, Malmö, Sweden
3 shared publicationsKari Hemminki
Center for Primary Health Care Research, Lund University/Region Skåne, Malmö, Sweden
3 shared publicationsLisa Jacobson
Department of Epidemiology, Johns Hopkins University, Baltimore, MD, USA
3 shared publications
Latest Publications
- Open Access
- 21 November 2015
- Published by Springer Nature in BMC Research Notes
- Vol. 8 (1) , 697
Lipid levels in HIV-positive men receiving anti-retroviral therapy are not associated with copy number variation of reverse cholesterol transport pathway genes
The exacerbation of HIV-1 associated dyslipidemia seen in a subset of patients receiving anti-retroviral therapy suggests that genetic factors put these individuals at greater risk of cardiovascular disease. Single nucleotide polymorphisms (SNPs) within genes of and influencing the reverse cholesterol transport (RCT) pathway are associated with lipid levels but little is known regarding their copy number variation (CNV). This form of quantitative genetic variation has the potential to alter the amount of gene product made, thereby also influencing lipid metabolism. To examine if CNV in RCT pathway genes was associated with altered serum lipid profiles in HIV-positive individuals receiving therapy, we designed a custom multiplex ligation-dependent probe amplification assay to screen 16 RCT genes within a subset of individuals from the Multicenter AIDS Cohort Study who show extreme lipid phenotypes. Verification of CNV was performed using a custom NanoString assay, and the Illumina HT-12 mRNA expression microarray was used to determine the influence of copy number on gene expression. Among the RCT genes, CNV was observed to be extremely rare. The only CNV seen was in the CETP gene, which showed a loss of copy in 1 of the 320 samples (0.3 %) in our study. The genes in our study showed little variation in expression between individuals, and the variation seen was not related to any detected CNV. Whole gene CNV is uncommon in RCT pathway genes, and not a major factor in the development of highly active antiretroviral therapy (HAART) associated dyslipidemia.
- 21 November 2015
- Published by Springer Nature in BMC Research Notes
- Vol. 8 (1) , 697
Open AccessLipid levels in HIV-positive men receiving anti-retroviral therapy are not associated with copy number variation of reverse cholesterol transport pathway genes
The exacerbation of HIV-1 associated dyslipidemia seen in a subset of patients receiving anti-retroviral therapy suggests that genetic factors put these individuals at greater risk of cardiovascular disease. Single nucleotide polymorphisms (SNPs) within genes of and influencing the reverse cholesterol transport (RCT) pathway are associated with lipid levels but little is known regarding their copy number variation (CNV). This form of quantitative genetic variation has the potential to alter the amount of gene product made, thereby also influencing lipid metabolism. To examine if CNV in RCT pathway genes was associated with altered serum lipid profiles in HIV-positive individuals receiving therapy, we designed a custom multiplex ligation-dependent probe amplification assay to screen 16 RCT genes within a subset of individuals from the Multicenter AIDS Cohort Study who show extreme lipid phenotypes. Verification of CNV was performed using a custom NanoString assay, and the Illumina HT-12 mRNA expression microarray was used to determine the influence of copy number on gene expression. Among the RCT genes, CNV was observed to be extremely rare. The only CNV seen was in the CETP gene, which showed a loss of copy in 1 of the 320 samples (0.3 %) in our study. The genes in our study showed little variation in expression between individuals, and the variation seen was not related to any detected CNV. Whole gene CNV is uncommon in RCT pathway genes, and not a major factor in the development of highly active antiretroviral therapy (HAART) associated dyslipidemia.
- 1 October 2014
- Published by Wolters Kluwer Health in JAIDS Journal of Acquired Immune Deficiency Syndromes
- Vol. 67 (2) , e84-e86
Comment on “Characteristics of B-Cell Lymphomas in HIV/HCV-Coinfected Patients During the Combined Antiretroviral Therapy Era
- 1 October 2014
- Published by Wolters Kluwer Health in JAIDS Journal of Acquired Immune Deficiency Syndromes
- Vol. 67 (2) , e84-e86
Comment on “Characteristics of B-Cell Lymphomas in HIV/HCV-Coinfected Patients During the Combined Antiretroviral Therapy Era
- 1 November 2013
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- Vol. 22 (11) , 2084-2093
Serum Biomarkers of Immune Activation and Subsequent Risk of Non-Hodgkin B-Cell Lymphoma among HIV-Infected Women
Background: There is increasing evidence that chronic immune activation predisposes to non-Hodgkin lymphoma (NHL). Whether this association exists among women representative of the current HIV epidemic in the United States who are at high risk of HIV-associated NHL (AIDS-NHL), remains to be determined. Methods: We conducted a nested case–control study within the Women's Interagency HIV Study with longitudinally collected risk factor data and sera. Cases were HIV-infected women with stored sera collected at three time-windows 3 to 5 years, 1 to 3 years, and 0 to 1 year before AIDS-NHL diagnosis (n = 22). Three to six HIV-infected controls, without AIDS-NHL, were matched to each case on age, race, CD4+ T-cell count, and study follow-up time (n = 78). ORs and 95% confidence intervals (CI) for the association between one unit increase in log-transformed biomarker levels and AIDS-NHL were computed using random effect multivariate logistic regression models. Results: Elevated levels of sCD27 (OR = 7.21; 95% CI, 2.62–19.88), sCD30 (OR = 2.64; 95% CI, 1.24–5.64), and CXCL13 (OR = 2.56; 95% CI, 1.32–4.96) were associated with subsequent diagnosis of AIDS-NHL overall. Elevated sCD23 was associated with a two to three-fold increased risk of AIDS-NHL in certain subgroups, whereas elevated interleukin 6 was associated with a two-fold increased risk in the 0 to 1 year time-window, only. Conclusions: These findings support the hypothesis that chronic B-cell activation contributes to the development of AIDS-NHL in women. Impact: Soluble CD23 (sCD23), sCD27, sCD30, and CXCL13 may serve as biomarkers for AIDS-NHL. Cancer Epidemiol Biomarkers Prev; 22(11); 2084–93. ©2013 AACR.
- 1 November 2013
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- Vol. 22 (11) , 2084-2093
Serum Biomarkers of Immune Activation and Subsequent Risk of Non-Hodgkin B-Cell Lymphoma among HIV-Infected Women
Background: There is increasing evidence that chronic immune activation predisposes to non-Hodgkin lymphoma (NHL). Whether this association exists among women representative of the current HIV epidemic in the United States who are at high risk of HIV-associated NHL (AIDS-NHL), remains to be determined. Methods: We conducted a nested case–control study within the Women's Interagency HIV Study with longitudinally collected risk factor data and sera. Cases were HIV-infected women with stored sera collected at three time-windows 3 to 5 years, 1 to 3 years, and 0 to 1 year before AIDS-NHL diagnosis (n = 22). Three to six HIV-infected controls, without AIDS-NHL, were matched to each case on age, race, CD4+ T-cell count, and study follow-up time (n = 78). ORs and 95% confidence intervals (CI) for the association between one unit increase in log-transformed biomarker levels and AIDS-NHL were computed using random effect multivariate logistic regression models. Results: Elevated levels of sCD27 (OR = 7.21; 95% CI, 2.62–19.88), sCD30 (OR = 2.64; 95% CI, 1.24–5.64), and CXCL13 (OR = 2.56; 95% CI, 1.32–4.96) were associated with subsequent diagnosis of AIDS-NHL overall. Elevated sCD23 was associated with a two to three-fold increased risk of AIDS-NHL in certain subgroups, whereas elevated interleukin 6 was associated with a two-fold increased risk in the 0 to 1 year time-window, only. Conclusions: These findings support the hypothesis that chronic B-cell activation contributes to the development of AIDS-NHL in women. Impact: Soluble CD23 (sCD23), sCD27, sCD30, and CXCL13 may serve as biomarkers for AIDS-NHL. Cancer Epidemiol Biomarkers Prev; 22(11); 2084–93. ©2013 AACR.
- 13 September 2013
- Published by Springer Nature in Familial Cancer
- Vol. 13 (1) , 45-56
Genetic variation at 8q24, family history of cancer, and upper gastrointestinal cancers in a Chinese population
Genetic variation at 8q24 is associated with prostate, bladder, breast, colorectal, thyroid, lung, ovarian, UADT, liver and stomach cancers. However, a role for variation at 8q24 in familial clustering of upper gastrointestinal cancers has not been studied. In order to explore potential inherited susceptibility, we analyzed epidemiologic data from a population-based case–control study of upper gastrointestinal cancers from Taixing, China. The study population includes 204 liver, 206 stomach, and 218 esophageal cancer cases and 415 controls. Associations between 8q24 rs1447295, rs16901979, rs6983267 and these cancers were stratified by family history of cancer. Odds ratios and 95 % confidence intervals were adjusted for potential confounders: age, sex, education, tobacco smoking, alcohol consumption, and BMI at interview. We also adjusted for hepatitis B and aflatoxin (liver cancer) and Helicobacter pylori (stomach cancer). In a dominant model, among those with a family history of cancer, rs1447295 was positively associated with liver cancer (ORadj 2.80; 95 % CI 1.15–6.80). Heterogeneity was observed (P heterogeneity = 0.029) with rs6983267 and liver cancer, with positive association in the dominant model among those with a family history of cancer and positive association in the recessive model among those without a family history of cancer. When considered in a genetic risk score model, each additional 8q24 risk genotype increased the odds of liver cancer by two-fold among those with a family history of cancer (ORadj 2.00; 95 % CI 1.15–3.47). These findings suggest that inherited susceptibility to liver cancer may exist in the Taixing population and that variation at 8q24 might be a genetic component of that inherited susceptibility.
- 13 September 2013
- Published by Springer Nature in Familial Cancer
- Vol. 13 (1) , 45-56
Genetic variation at 8q24, family history of cancer, and upper gastrointestinal cancers in a Chinese population
Genetic variation at 8q24 is associated with prostate, bladder, breast, colorectal, thyroid, lung, ovarian, UADT, liver and stomach cancers. However, a role for variation at 8q24 in familial clustering of upper gastrointestinal cancers has not been studied. In order to explore potential inherited susceptibility, we analyzed epidemiologic data from a population-based case–control study of upper gastrointestinal cancers from Taixing, China. The study population includes 204 liver, 206 stomach, and 218 esophageal cancer cases and 415 controls. Associations between 8q24 rs1447295, rs16901979, rs6983267 and these cancers were stratified by family history of cancer. Odds ratios and 95 % confidence intervals were adjusted for potential confounders: age, sex, education, tobacco smoking, alcohol consumption, and BMI at interview. We also adjusted for hepatitis B and aflatoxin (liver cancer) and Helicobacter pylori (stomach cancer). In a dominant model, among those with a family history of cancer, rs1447295 was positively associated with liver cancer (ORadj 2.80; 95 % CI 1.15–6.80). Heterogeneity was observed (P heterogeneity = 0.029) with rs6983267 and liver cancer, with positive association in the dominant model among those with a family history of cancer and positive association in the recessive model among those without a family history of cancer. When considered in a genetic risk score model, each additional 8q24 risk genotype increased the odds of liver cancer by two-fold among those with a family history of cancer (ORadj 2.00; 95 % CI 1.15–3.47). These findings suggest that inherited susceptibility to liver cancer may exist in the Taixing population and that variation at 8q24 might be a genetic component of that inherited susceptibility.
- 1 February 2013
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- Vol. 22 (2) , 295-307
Serum Levels of the Chemokine CXCL13, Genetic Variation inCXCL13and Its Receptor CXCR5, and HIV-Associated Non-Hodgkin B-Cell Lymphoma Risk
Background: CXCL13 and CXCR5 are a chemokine and receptor pair whose interaction is critical for naïve B-cell trafficking and activation within germinal centers. We sought to determine whether CXCL13 levels are elevated before HIV-associated non-Hodgkin B-cell lymphoma (AIDS-NHL), and whether polymorphisms in CXCL13 or CXCR5 are associated with AIDS-NHL risk and CXCL13 levels in a large cohort of HIV-infected men. Methods: CXCL13 levels were measured in sera from 179 AIDS-NHL cases and 179 controls at three time-points. TagSNPs in CXCL13 (n = 16) and CXCR5 (n = 11) were genotyped in 183 AIDS-NHL cases and 533 controls. OR and 95% confidence intervals (CI) for the associations between one unit increase in log CXCL13 levels and AIDS-NHL, as well as tagSNP genotypes and AIDS-NHL, were computed using logistic regression. Mixed linear regression was used to estimate mean ratios (MR) for the association between tagSNPs and CXCL13 levels. Results: CXCL13 levels were elevated for more than 3 years (OR = 3.24; 95% CI = 1.90–5.54), 1 to 3 years (OR = 3.39; 95% CI = 1.94–5.94), and 0 to 1 year (OR = 3.94; 95% CI = 1.98–7.81) before an AIDS-NHL diagnosis. The minor allele of CXCL13 rs355689 was associated with reduced AIDS-NHL risk (ORTCvsTT = 0.65; 95% CI = 0.45–0.96) and reduced CXCL13 levels (MRCCvsTT = 0.82; 95% CI = 0.68–0.99). The minor allele of CXCR5 rs630923 was associated with increased CXCL13 levels (MRAAvsTT = 2.40; 95% CI = 1.43–4.50). Conclusions: CXCL13 levels were elevated preceding an AIDS-NHL diagnosis, genetic variation in CXCL13 may contribute to AIDS-NHL risk, and CXCL13 levels may be associated with genetic variation in CXCL13 and CXCR5. Impact: CXCL13 may serve as a biomarker for early AIDS-NHL detection. Cancer Epidemiol Biomarkers Prev; 22(2); 295–307. ©2012 AACR.
- 1 February 2013
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- Vol. 22 (2) , 295-307
Serum Levels of the Chemokine CXCL13, Genetic Variation inCXCL13and Its Receptor CXCR5, and HIV-Associated Non-Hodgkin B-Cell Lymphoma Risk
Background: CXCL13 and CXCR5 are a chemokine and receptor pair whose interaction is critical for naïve B-cell trafficking and activation within germinal centers. We sought to determine whether CXCL13 levels are elevated before HIV-associated non-Hodgkin B-cell lymphoma (AIDS-NHL), and whether polymorphisms in CXCL13 or CXCR5 are associated with AIDS-NHL risk and CXCL13 levels in a large cohort of HIV-infected men. Methods: CXCL13 levels were measured in sera from 179 AIDS-NHL cases and 179 controls at three time-points. TagSNPs in CXCL13 (n = 16) and CXCR5 (n = 11) were genotyped in 183 AIDS-NHL cases and 533 controls. OR and 95% confidence intervals (CI) for the associations between one unit increase in log CXCL13 levels and AIDS-NHL, as well as tagSNP genotypes and AIDS-NHL, were computed using logistic regression. Mixed linear regression was used to estimate mean ratios (MR) for the association between tagSNPs and CXCL13 levels. Results: CXCL13 levels were elevated for more than 3 years (OR = 3.24; 95% CI = 1.90–5.54), 1 to 3 years (OR = 3.39; 95% CI = 1.94–5.94), and 0 to 1 year (OR = 3.94; 95% CI = 1.98–7.81) before an AIDS-NHL diagnosis. The minor allele of CXCL13 rs355689 was associated with reduced AIDS-NHL risk (ORTCvsTT = 0.65; 95% CI = 0.45–0.96) and reduced CXCL13 levels (MRCCvsTT = 0.82; 95% CI = 0.68–0.99). The minor allele of CXCR5 rs630923 was associated with increased CXCL13 levels (MRAAvsTT = 2.40; 95% CI = 1.43–4.50). Conclusions: CXCL13 levels were elevated preceding an AIDS-NHL diagnosis, genetic variation in CXCL13 may contribute to AIDS-NHL risk, and CXCL13 levels may be associated with genetic variation in CXCL13 and CXCR5. Impact: CXCL13 may serve as a biomarker for early AIDS-NHL detection. Cancer Epidemiol Biomarkers Prev; 22(2); 295–307. ©2012 AACR.
- Open Access
- 22 December 2012
- Published by Wiley in International Journal of Cancer
- Vol. 133 (1) , 201-213
Nucleotide variation in IL‐10 and IL‐12 and their receptors and cervical and vulvar cancer risk: A hybrid case–parent triad and case–control study
Given the important role of cell mediated immunity in viral clearance and control of premalignant lesions, we hypothesize that variation in the IL‐12/IL‐10 cytokine and cytokine receptor genes may influence cervical and vulvar cancer risk. We evaluated 76 tagSNPs from seven candidate genes (IL-10, IL-12A, IL-12B, IL-10RA, IL-10RB, IL-12RB1, and IL12RB2) in case–parent sets (n=43 cervical squamous cell carcinoma (SCC), n=96 cervical adenocarcinoma, n=53 vulvar SCC), additional cases (n=356 cervical SCC, n=406 cervical adenocarcinoma, and n=473 vulvar SCC) and population based controls (1,111). We calculated log‐additive odds ratios (ORs) and 95% confidence intervals (CIs) for the association between tagSNP and cancer risk using a pseudo‐likelihood based method which combined genotype information on cases, parents, and population controls. After correction for multiple comparisons, we identified several statistically significant SNP associations. Cervical SCC risk was associated with the minor alleles of the IL10RA rs9610 3’ UTR SNP (OR=1.76, 95% CI=1.15–2.68) and two synonymous IL12RB2 SNPs (rs4297265, OR=0.46, 95% CI=0.26–0.82; rs2229546, OR=0.43, 95% CI=0.21–0.87). Cervical adenocarcinoma risk was associated with the minor alleles of the IL10RA rs4252314 intronic SNP (OR=2.23, 95% CI=1.26–3.96) and IL12RB1 rs11575934 non‐synonymous SNP (OR=1.51, 95% CI=1.12–2.05). Finally, the minor allele of the IL12B rs3181224 3’ UTR SNP was associated with a reduced risk of vulvar SCC (OR=0.30, 95% CI=0.12–0.74). These results raise the possibility that a shift in the balance of the immune response due to genetic variants in key cytokine genes could influence the development of cervical and vulvar cancer.
- 22 December 2012
- Published by Wiley in International Journal of Cancer
- Vol. 133 (1) , 201-213
Open AccessNucleotide variation in IL‐10 and IL‐12 and their receptors and cervical and vulvar cancer risk: A hybrid case–parent triad and case–control study
Given the important role of cell mediated immunity in viral clearance and control of premalignant lesions, we hypothesize that variation in the IL‐12/IL‐10 cytokine and cytokine receptor genes may influence cervical and vulvar cancer risk. We evaluated 76 tagSNPs from seven candidate genes (IL-10, IL-12A, IL-12B, IL-10RA, IL-10RB, IL-12RB1, and IL12RB2) in case–parent sets (n=43 cervical squamous cell carcinoma (SCC), n=96 cervical adenocarcinoma, n=53 vulvar SCC), additional cases (n=356 cervical SCC, n=406 cervical adenocarcinoma, and n=473 vulvar SCC) and population based controls (1,111). We calculated log‐additive odds ratios (ORs) and 95% confidence intervals (CIs) for the association between tagSNP and cancer risk using a pseudo‐likelihood based method which combined genotype information on cases, parents, and population controls. After correction for multiple comparisons, we identified several statistically significant SNP associations. Cervical SCC risk was associated with the minor alleles of the IL10RA rs9610 3’ UTR SNP (OR=1.76, 95% CI=1.15–2.68) and two synonymous IL12RB2 SNPs (rs4297265, OR=0.46, 95% CI=0.26–0.82; rs2229546, OR=0.43, 95% CI=0.21–0.87). Cervical adenocarcinoma risk was associated with the minor alleles of the IL10RA rs4252314 intronic SNP (OR=2.23, 95% CI=1.26–3.96) and IL12RB1 rs11575934 non‐synonymous SNP (OR=1.51, 95% CI=1.12–2.05). Finally, the minor allele of the IL12B rs3181224 3’ UTR SNP was associated with a reduced risk of vulvar SCC (OR=0.30, 95% CI=0.12–0.74). These results raise the possibility that a shift in the balance of the immune response due to genetic variants in key cytokine genes could influence the development of cervical and vulvar cancer.
- 1 November 2012
- Published by American Association for Cancer Research (AACR) in Cancer Prevention Research
- Vol. 5 (11_Supplem) , A107
Abstract A107: Variation in the prolactin and prolactin receptor genes and familial breast cancer
Background: Breast cancer aggregates within some families, accounting for about 25% of incident cases. Known genetic variants, such as BRCA1/BRCA2 mutations, account for less than 10% of these familial breast cancer cases, thus, research into additional risk or protective genetic factors for familial breast cancer may provide valuable information for risk stratification. Serum levels of prolactin have been associated with sporadic breast cancer risk in previous studies. We sought to test the hypothesis that variation in the genes coding for prolactin (PRL) and the prolactin receptor (PRLR) would be associated with increased or decreased risk of familial breast cancer. Methods: We designed a case-control study of probands recruited between 1998 and 2009 by the UCLA Family Cancer Registry; a population enriched with women having a strong family history of breast cancer and BRCA1/BRCA2 mutation carriers. Genotyping of tagSNPs in PRL (n=11) and PRLR (n=28) was performed in 351 unrelated women who developed breast cancer and 290 unaffected controls with similar family histories to the cases. Multivariate logistic regression models controlling for age, Ashkenazi Jewish heritage, education, and number of affected relatives were used to calculate odds ratios (ORs) and 95% confidence intervals (CIs) for the association between SNPs and familial breast cancer. Genotype specific ORs as well as per-allele (additive model) ORs were calculated. Results: Familial breast cancer risk was inversely associated with carriership of the minor alleles for three PRLR SNPs in the additive models, rs9292573 (OR=0.7, 95% CI=0.5-0.9), rs10805603 (OR=0.6, 95% CI=0.4-0.9), and rs1587607 (OR=0.7, 95% CI=0.5-1.0). PRLR SNP rs249522 was associated with increased risk of cancer in the additive model (OR=1.8, 95% CI =1.2-2.7). Minor allele carriers of the PRL SNP rs12210179, located in a putative transcription factor binding site, had a decreased risk of cancer in the additive model (OR=0.7, 95% CI=0.5-0.9). Conclusion: These data suggest that genetic variation in PRL and PRLR are associated with breast cancer in a population with a strong family history of breast cancer. Citation Format: Shehnaz K. Hussain, Mary Sehl, Daniel Conn, Janet S. Sinsheimer, Uma Dandekar, Jeanette Papp, Zuo-Feng Zhang, Patricia A. Ganz. Variation in the prolactin and prolactin receptor genes and familial breast cancer. [abstract]. In: Proceedings of the Eleventh Annual AACR International Conference on Frontiers in Cancer Prevention Research; 2012 Oct 16-19; Anaheim, CA. Philadelphia (PA): AACR; Cancer Prev Res 2012;5(11 Suppl):Abstract nr A107.
- 1 November 2012
- Published by American Association for Cancer Research (AACR) in Cancer Prevention Research
- Vol. 5 (11_Supplem) , A107
Abstract A107: Variation in the prolactin and prolactin receptor genes and familial breast cancer
Background: Breast cancer aggregates within some families, accounting for about 25% of incident cases. Known genetic variants, such as BRCA1/BRCA2 mutations, account for less than 10% of these familial breast cancer cases, thus, research into additional risk or protective genetic factors for familial breast cancer may provide valuable information for risk stratification. Serum levels of prolactin have been associated with sporadic breast cancer risk in previous studies. We sought to test the hypothesis that variation in the genes coding for prolactin (PRL) and the prolactin receptor (PRLR) would be associated with increased or decreased risk of familial breast cancer. Methods: We designed a case-control study of probands recruited between 1998 and 2009 by the UCLA Family Cancer Registry; a population enriched with women having a strong family history of breast cancer and BRCA1/BRCA2 mutation carriers. Genotyping of tagSNPs in PRL (n=11) and PRLR (n=28) was performed in 351 unrelated women who developed breast cancer and 290 unaffected controls with similar family histories to the cases. Multivariate logistic regression models controlling for age, Ashkenazi Jewish heritage, education, and number of affected relatives were used to calculate odds ratios (ORs) and 95% confidence intervals (CIs) for the association between SNPs and familial breast cancer. Genotype specific ORs as well as per-allele (additive model) ORs were calculated. Results: Familial breast cancer risk was inversely associated with carriership of the minor alleles for three PRLR SNPs in the additive models, rs9292573 (OR=0.7, 95% CI=0.5-0.9), rs10805603 (OR=0.6, 95% CI=0.4-0.9), and rs1587607 (OR=0.7, 95% CI=0.5-1.0). PRLR SNP rs249522 was associated with increased risk of cancer in the additive model (OR=1.8, 95% CI =1.2-2.7). Minor allele carriers of the PRL SNP rs12210179, located in a putative transcription factor binding site, had a decreased risk of cancer in the additive model (OR=0.7, 95% CI=0.5-0.9). Conclusion: These data suggest that genetic variation in PRL and PRLR are associated with breast cancer in a population with a strong family history of breast cancer. Citation Format: Shehnaz K. Hussain, Mary Sehl, Daniel Conn, Janet S. Sinsheimer, Uma Dandekar, Jeanette Papp, Zuo-Feng Zhang, Patricia A. Ganz. Variation in the prolactin and prolactin receptor genes and familial breast cancer. [abstract]. In: Proceedings of the Eleventh Annual AACR International Conference on Frontiers in Cancer Prevention Research; 2012 Oct 16-19; Anaheim, CA. Philadelphia (PA): AACR; Cancer Prev Res 2012;5(11 Suppl):Abstract nr A107.
- Open Access
- 19 April 2012
- Published by Springer Nature in Infectious Agents and Cancer
- Vol. 7 (1) , P25
Ultraviolet radiation exposure and HIV-associated non-Hodgkin lymphoma risk
- 19 April 2012
- Published by Springer Nature in Infectious Agents and Cancer
- Vol. 7 (1) , P25
Open AccessUltraviolet radiation exposure and HIV-associated non-Hodgkin lymphoma risk
- Open Access
- 19 April 2012
- Published by Springer Nature in Infectious Agents and Cancer
- Vol. 7 (S1) , O26
Risk factors for squamous cell skin cancer in HIV
- 19 April 2012
- Published by Springer Nature in Infectious Agents and Cancer
- Vol. 7 (S1) , O26
Open AccessRisk factors for squamous cell skin cancer in HIV
- Open Access
- 11 October 2010
- Published by Springer Nature in Infectious Agents and Cancer
- Vol. 5 (1) , A24-1
Elevated serum levels of CXCL13 precede HIV-associated non-Hodgkin’s lymphoma
- 11 October 2010
- Published by Springer Nature in Infectious Agents and Cancer
- Vol. 5 (1) , A24-1
Open AccessElevated serum levels of CXCL13 precede HIV-associated non-Hodgkin’s lymphoma